Baxter Announces Vantive as the Name of Proposed Kidney Care Spinoff
25 Julho 2023 - 9:15AM
Business Wire
Baxter International Inc. (NYSE:BAX), a global medtech leader,
today announced that Vantive will be the name of the company’s
proposed spinoff of its Renal Care and Acute Therapies businesses.
Vantive is expected to launch as an independent, publicly traded
company by July 2024 or earlier, subject to satisfaction of
customary conditions.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230725407762/en/
“Announcing the Vantive name is a critical milestone in our
journey to becoming an independent company focused solely on
therapies for kidney disease and other vital organ support,” said
Chris Toth, executive vice president and group president, Kidney
Care at Baxter, who is to serve as chief executive officer of the
new company upon spinoff. “The Vantive name reflects our dedicated
employees’ steadfast commitment to patients and our passion for
helping them lead full and meaningful lives in partnership with our
customers. We are eager to continue collaborating with the kidney
and critical care communities as we work to transform care
globally.”
Vantive will carry forward Baxter’s nearly 70-year legacy as a
pioneer and leader in kidney disease and organ support therapies.
The company will continue to serve as a trusted partner to
providers and clinicians around the world, focusing on improving
outcomes for the more than one million patients it serves annually
in more than 70 countries. Vantive will continue its focus on
driving meaningful change in kidney care and organ support through
innovative technologies, digital connectivity, and services to
better support clinicians and patients. As a standalone entity with
its own investment priorities and enhanced management focus,
Vantive should be better positioned to pursue growth opportunities
and invest in innovation.
The Vantive logo and full visual identity will be unveiled at a
later date. Until completion of the proposed separation in 2024,
the Kidney Care business will continue to operate as Baxter. Read
more about the proposed Kidney Care spinoff here.
About Baxter
Every day, millions of patients, caregivers and healthcare
providers rely on Baxter’s leading portfolio of diagnostic,
critical care, kidney care, nutrition, hospital and surgical
products used across patient homes, hospitals, physician offices
and other sites of care. For more than 90 years, we’ve been
operating at the critical intersection where innovations that save
and sustain lives meet the healthcare providers who make it happen.
With products, digital health solutions and therapies available in
more than 100 countries, Baxter’s employees worldwide are now
building upon the company’s rich heritage of medical breakthroughs
to advance the next generation of transformative healthcare
innovations. To learn more, visit www.baxter.com and follow us on
Twitter, LinkedIn and Facebook.
This release includes forward-looking statements concerning the
company’s planned spinoff of its Renal Care and Acute Therapies
businesses, related timing and anticipated benefits. These
forward-looking statements are based on assumptions about many
important factors, including the following, which could cause
actual results to differ materially from those in the
forward-looking statements: the company’s ability to execute and
complete the proposed spinoff; the timing for the proposed spinoff;
the ability to satisfy the conditions to the proposed spinoff; and
other risks identified in Baxter’s most recent filings on Form 10-K
and Form 10-Q and other SEC filings, all of which are available on
Baxter’s website. Baxter does not undertake to update its
forward-looking statements unless otherwise required by the federal
securities laws.
Baxter and Vantive are trademarks of Baxter International Inc.
or its subsidiaries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230725407762/en/
Media Contact Lauren Russ, (224) 948-5353
media@baxter.com
Investor Contact Clare Trachtman, (224) 948-3020
Baxter (NYSE:BAX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Baxter (NYSE:BAX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024